INTRODUCTION
============

The worldwide prevalence of diabetes is increasing; preventing its onset and development is a healthcare priority.^[@ref1])^ The cornerstone of diabetes treatment is improvement of lifestyle, with management of weight and physical activity because it is effective both for prevention of diabetes onset^[@ref2]-[@ref5])^ and good metabolic control of diabetes.^[@ref6],[@ref7])^ Both the American Diabetes Association and Japanese Diabetes Society recommend exercise therapy that combines aerobic exercise and resistance movement.^[@ref8],[@ref9])^ Nonexercise activity thermogenesis (NEAT) has been reported to be involved in control of obesity and diabetes aggravation.^[@ref10]-[@ref13])^ However, lifestyle intervention requires extensive use of human resources and is costly. Further, it is not easy for healthcare professionals (HCPs) to evaluate patient lifestyle during consultations.

The Internet of Things (IoT) enables networking and connection of objects to the Internet, and has expanded sufficiently to allow connection of wearable devices and measurement instruments such as body-weight scales with Bluetooth or near field communication (NFC). It is thus easy to record health data and transfer it to cloud services where it is accessible by both patients themselves and their physicians. These technologies make it possible to collect large volumes of health data such as daily activity, body weight (BW), and blood pressure (BP) automatically. Applications compatible with devices that measure health-related data are readily available, and some have been evaluated.^[@ref14]-[@ref17])^ However, these applications are designed primarily to present data to the user; the feedback functions are limited.

In previous randomized clinical trials evaluating the use of IoT devices in diabetic patients,^[@ref18]-[@ref21])^ the control groups were not given measuring instruments comparable to the intervention group.^[@ref18]-[@ref21])^ Therefore, the outcomes of the intervention included effects of both the health data measurement itself and the feedback using IoT. To evaluate the effectiveness of diabetes health guidance using IoT, evaluation of the feedback using collected data is required.

For this study, we developed a new health guidance system (the "IoT system") using IoT technologies. Daily health activity data and BW and BP are linked to each other and collected, and are then provided for the patients themselves and HCPs using the application and an Internet cloud service. The IoT system enables HCPs to evaluate patient lifestyle and to provide appropriate feedback. The effect of the IoT-system feedback is to be compared with those obtained in a control group using health measurement instruments that do not have a data transmission function, but allowed self-management of health data. Data were provided not only to the primary care physicians for feedback but also to study investigator HCPs in a remote call center for feedback using the IoT system. Providing these patient health data to HCPs may contribute to improved control of diabetes, BW and BP through self-management and more appropriate health guidance by HCPs.

In this manuscript, we outline the study protocol of the randomized controlled trial designed to evaluate the effect of the IoT-system; we also report the characteristics of registrants at the time of registration completion.

METHODS
=======

Trial design
------------

This multicenter, open-label, randomized (1:1), parallel group study is designed to compare the impact of intensive health guidance on diabetic outpatients using an IoT system with conventional medical guidance on glucose control. The study protocol was approved by the ethical committee of Nagoya University Graduate School of Medicine (No. 2016-0152). All enrolled patients provided written consent to participate after they were informed of the purpose of the study as well as the potential risks and benefits. The trial is listed in the Japanese University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR: UMIN 000022480).

Patients
--------

Patients are eligible for inclusion if they 1) are outpatients at the two participating clinics, and 2) have glycosylated hemoglobin (HbA1c) ≥ 6.5%. Patients are excluded if they 1) are on dialysis, 2) are treated with insulin, 3) have severe diabetic nephropathy (estimated glomerular filtration rate \< 30 mL/min/1.73 m^2^), 4) cannot properly operate the devices to be used, or 5) are judged by their physician as not able to participate.

Registration and randomization
------------------------------

Participants are recruited from two participating clinics where they meet with the study coordinator who provides them with an information brochure and a consent form. After consent, the coordinator has access to a web-based registration and follow-up system developed by the Center for Advanced Medical and Clinical Research of the Nagoya University Hospital and enters the information required for enrollment. The system automatically determines the eligibility of each patient and randomly assigns him/her in equal numbers to the IoT or non-IoT group with a dynamic allocation strategy using a minimization method. Stratification includes the clinic that the patient visits, HbA1c (\>8% or ≤8%), sex, age (\>65 or ≤65), BMI (\>25 kg/m^2^ or ≤25 kg/m^2^), and the use or nonuse of oral diabetes agents.

Interventions
-------------

Patients in the IoT group are provided with smartphones (Kyocera S301, Kyoto, Japan) programmed with the study-specific application (<https://play.google.com/store/apps/details?id=jp.ac.nagoyau.lifestylemonitoring&hl=ja>), Bluetooth-enabled activity trackers (TOSHIBA Actiband WERAM1100, Tokyo, Japan), Bluetooth-enabled BP monitors (A&D UA-851PBT-C, Tokyo, Japan), and Bluetooth-enabled body weight scales (A&D UC-411PBT-C). All devices can transmit measurement data over a wireless network to a cloud server. IoT system patients, primary care physicians (local HCPs) and study investigator HCP in a remote call center (remote HCP) can view the health data (exercise volume, exercise time, step counts, circadian rhythm, changes in BW and changes in BP, and number of access events) transmitted by each smartphone. Remote HCP at the call center call patients once monthly to provide feedback the accomplishment of personal goals, activity volume, and weight change.

Patients in the non-IoT group are provided with an ordinary activity trackers (Omron HJ-325, Kyoto, Japan), BP monitors (Omron HEM-7130-HP), and body weight scales (Tanita HD-660, Tokyo, Japan) that cannot transmit data over a wireless network. Participants in this self-managed control group use these conventional measurement instruments without routine physician or investigator feedback.

An overview of IoT system is shown in [Figure 1](#fig1){ref-type="fig"}, and a study flowchart is shown in [Figure 2](#fig2){ref-type="fig"}.

![An overview of the IoT system\
Patients in the IoT group were provided with smartphones programmed with the study-specific application, activity trackers, BP monitors, and weight scales, all able to transmit measurement data by wireless network to a cloud server. Patients in the non-IoT group were provided with an ordinary activity tracker, BP monitors, and weight scales under the self-management of patients. IoT, Internet of Things; HCP, healthcare professional; BP, and blood pressure.](2186-3326-79-0323-g001){#fig1}

![Study flowchart. IoT, Internet of Things; HCP, healthcare professional](2186-3326-79-0323-g002){#fig2}

Outcomes
--------

The primary outcome is glucose control measured by HbA1c at 6 months. Secondary outcomes include change in BW, BP, fasting blood glucose, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and changes of medication.

Sample size
-----------

Based on the results of a previous clinical trial,^[@ref22],[@ref23])^ the geometric standard deviation (SD) of change in HbA1c at the last observation period was assumed to be 0.7%. We estimated that at least 48 patients were required in each treatment group to confer a power of 80% to detect a significant difference of 0.4% change from baseline in the two groups at the end of the intervention. We thus planned to recruit 50 patients per group (100 in total) with consideration for potential discontinuation or dropout of enrolled patients during the study period.

Statistical analysis
--------------------

Continuous variables were expressed as means ± SD. Between-group differences in baseline values of continuous variables were tested for significance with the two-sample *t*-test, and values of nominal variables were compared using the Chi-square test. The primary outcome, change in HbA1c from baseline to 6 months, will be evaluated in each group and compared by analysis of covariance (ANCOVA). Baseline HbA1c, sex, age, BMI, and the use or nonuse of diabetes oral agents were included as covariates. A linear mixed model including treatment period, treatment group, an interaction term for treatment group and period, HbA1c at entry, sex, age, BMI at entry, and the use or nonuse of diabetes oral agents as fixed effects will be used to compare the change in HbA1c from baseline at 3 and 6 months in the two groups.

Secondary outcomes, (BW, BP, fasting blood glucose, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides at 3 and 6 months), will be analyzed with linear-mixed effect models that include treatment period, treatment group, an interaction term between treatment group and period, value at entry, sex, age, BMI at entry, and the use or nonuse of diabetes oral agents as fixed effects. Changes of medication are classified as increased dose, no change, and decreased dose, and analyzed using the Mantel-extension test stratified by sex, age (\>65 or ≤65), BMI at entry (\>25 kg/m^2^ or ≤25 kg/m^2^), and the use or nonuse of diabetes oral agents. Differences are considered significant at P \<0.05 for all statistical analyses.

RESULTS
=======

The study enrolled 101 patients, 50 in the IoT group and 51 in the non-IoT group, at the two participating outpatient clinics. Baseline characteristics are shown in [Table 1](#table1){ref-type="table"}. The mean participant age was 57.1 ± 12.5 years, 45% were women, the mean BMI was 26.2 ± 4.8 kg/m^2^, mean HbA1c was 7.2 ± 0.6%, and mean fasting blood glucose was 145 ± 45 mg/dL. No between-group differences in baseline characteristics were observed except for triglycerides, which were lower in the IoT group than in the non-IoT group (P = 0.01). There were no intervention-related severe adverse events.

###### 

Baseline characteristics of the study population

  -----------------------------------------------------------------------------------
                                  Total\      IoT\           non-IoT\       P-value
                                  (n=101)     group (n=50)   group (n=51)   
  ------------------------------- ----------- -------------- -------------- ---------
  HbA1c (%)                       7.2±0.6     7.2±0.6        7.2±0.7        0.92

  Age (years)                     57.1±12.5   56.8±13.0      57.4±12.1      0.81

  Sex                                                                       

  Female                          45          23             22             0.19

  Male                            56          27             29             

  Body weight (kg)                70.4±16.1   71.3±16.3      69.4±16.0      0.54

  Body mass index (kg/m^2^)       26.2±4.8    26.4±4.8       26.1±4.9       0.75

  Blood pressure (mmHg)                                                     

  Systolic blood pressure         125±12      125±11         124±13         0.51

  Diastolic blood pressure        75±8        74±9           75±8           0.68

  Blood glucose (mg/dl)           145±45      138±41         152±47         0.13

  Total cholesterol (mg/dl)       191±41      187±39         195±43         0.30

  Triglyceride (mg/dl)            170±104     144±73         196±123        0.01

  HDL cholesterol (mg/dl)         53±14       51±12          54±17          0.29

  LDL cholesterol (mg/dl)         107±31      107±34         107±28         0.95

  Serum creatinine (mg/dl)        0.68±0.19   0.69±0.21      0.66±0.18      0.44

  Use of hypoglycemic drugs       96          48             48             0.56

  Use of antihypertensive drugs   47          21             26             0.21

  Use of lipid-lowering drugs     50          24             26             0.66
  -----------------------------------------------------------------------------------

IoT, Internet of Things; HDL, high-density lipoprotein; LDL, low-density lipoprotein. Data are means ± standard deviation.

DISCUSSION
==========

The IoT refers to the creation of networks of devices other than computers that contain electronics, applications, and/or sensors, and that have Internet connectivity. Using the IoT, new possibilities may be created by uploading health data from health measurement instruments such as activity metering devices, body weight scales and blood pressure monitors to Internet sites. The vast amount of health data collected using IoT can provide more information than previously possible to both patients and HCPs. A significant benefit of the IoT is the provision of patient-appropriate feedback by HCPs based on the large amount of collected and transmitted data.

A few clinical trials of IoT devices have been conducted in diabetic patients,^[@ref18]-[@ref21])^ but they did not evaluate the effect of feedback based on evaluation of IoT data. This study will be the first randomized controlled study to purely evaluate the effect of intensive feedback from HCPs using IoT. The study results will provide much needed information on the use of health data collected from internet-connected devices and the provision of IoT system feedback suitable for diabetes support. Such a system will be economical and will make effective use of limited medical resources.
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